

Markel Group vs Nomura
Specialty insurer combining insurance and investment activities vs Publicly traded company. Which is the better buy for your portfolio in August 2026? Plain-English answer below.
Markel Group operates as a specialty insurer with a growing portfolio of industrial and service businesses bolted on, effectively functioning as a mini-Berkshire Hathaway, while Nomura is Japan's largest investment bank connecting global capital markets to Japanese issuers and investors. Both firms are deeply involved in capital allocation at scale, though one does it through insurance float and the other through brokerage and underwriting. Read the Markel Group vs Nomura comparison to see how specialty insurance compounding and investment banking economics produce radically different risk and return profiles.
Markel Group operates as a specialty insurer with a growing portfolio of industrial and service businesses bolted on, effectively functioning as a mini-Berkshire Hathaway, while Nomura is Japan's larg...
Why It’s Moving

Markel stays under pressure as cautious analyst calls outweigh steady operating results.
- Analysts remain cautious on Markel after its early-August second-quarter update showed operating revenue holding flat year over year, reinforcing the view that growth is steady but not accelerating.
- Recent broker commentary has tilted defensive, with several firms maintaining Hold-equivalent ratings and one recent downgrade to Underperform, which has kept expectations subdued despite the company’s stable insurance footprint.
- Recent investor buying headlines, including large new positions from institutions, suggest some long-term confidence in Markel’s balance sheet and underwriting model, but they have not been enough to shift the broader cautious tone.

Markel stays under pressure as cautious analyst calls outweigh steady operating results.
- Analysts remain cautious on Markel after its early-August second-quarter update showed operating revenue holding flat year over year, reinforcing the view that growth is steady but not accelerating.
- Recent broker commentary has tilted defensive, with several firms maintaining Hold-equivalent ratings and one recent downgrade to Underperform, which has kept expectations subdued despite the company’s stable insurance footprint.
- Recent investor buying headlines, including large new positions from institutions, suggest some long-term confidence in Markel’s balance sheet and underwriting model, but they have not been enough to shift the broader cautious tone.
Investment Analysis

Markel Group
MKL
Pros
- Markel’s diversified business model—spanning insurance, investing, and a range of non-insurance operations—provides resilience and multiple growth avenues.
- Recent quarters show improved underwriting results, with gross premiums up 11% and adjusted operating income rising 24% year-over-year, reflecting operational momentum.
- The company maintains a conservative balance sheet with a low debt-to-equity ratio of 0.25, supporting financial flexibility and prudent capital allocation.
Considerations
- Operating income has declined sharply due to equity market volatility, dropping 26% in the latest quarter, exposing earnings to investment portfolio swings.
- Markel’s current and quick ratios are below 1.0, indicating potential near-term liquidity constraints relative to industry peers.
- Despite long-term outperformance, Markel’s recent stock price gains have lagged broader insurance indices, and it remains less liquid and well-known than mega-cap peers.

Nomura
NMR
Pros
- Nomura is the leading Japanese investment bank and securities firm, with a dominant domestic franchise and expanding footprint in key Asian growth markets.
- Its global markets division—including fixed income, equities, and treasury—has shown resilience to macroeconomic shocks, with a strong focus on institutional clients.
- Nomura’s recent restructuring efforts aim to sharpen focus on core businesses, cut costs, and enhance profitability, with targeted efficiency improvements underway.
Considerations
- Nomura’s profitability is highly sensitive to global capital markets activity, creating earnings volatility in periods of market stress or low trading volumes.
- The firm continues to face legacy legal and regulatory challenges from past international operations, which could impact future financial results.
- Intense competition in Asia from global banks and local rivals pressures margins and raises hurdles for share gains outside its home market.
next-earnings-date-heading
The next earnings date for MKL is expected on November 4, 2026, based on its usual reporting pattern. This report should cover Q3 2026 results. Markel Group has not formally confirmed the date yet, so it remains an estimated schedule.
next-earnings-date-heading
The next earnings date for MKL is expected on November 4, 2026, based on its usual reporting pattern. This report should cover Q3 2026 results. Markel Group has not formally confirmed the date yet, so it remains an estimated schedule.
Buy MKL or NMR in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.


